Screener
Zevra Therapeutics, Inc. ZVRA Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 95.5%+23.5pp | 86.1%+7.2pp | 84.5%+15.9pp | 80.7%+13.5pp | 72%-3.2pp | |
| Net margin | 42.8%+38.6pp | 101.6%+328pp | 78.2%+525pp | 41.9%+408pp | 4.3%+286pp | |
| Returns | ||||||
| Return on equity | 34.8%+31.3pp | 100.7%+305pp | 85.7%+294pp | 34.8%+171pp | 3.5%+150pp | |
| Return on invested capital | 71.7%+136pp | -0.1%+185pp | -49.9%+141pp | -53.2%+120pp | -64.6%— | |
| Efficiency | ||||||
| Asset turnover | 0.5×+0.2× | 0.5×+0.3× | 0.5×+0.3× | 0.4×+0.2× | 0.3×+0.1× | |
| Liquidity | ||||||
| Current ratio | 5.2×-2.7× | 4.9×+1.9× | 5.7×+3.2× | 8.6×+5.7× | 7.9×+5.9× | |
| Leverage | ||||||
| Debt-to-equity | 0×-0.5× | 0×-1.5× | 0.4×-1.1× | 0.5×-0.4× | 0.5×-1.3× | |
| Net debt / EBITDA | -1.6×— | -35.8×— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $3.55+70.5% | $3.42+351% | $2.70+215% | $2.38+63.1% | $2.08+169% | |
| Valuation | ||||||
| Market capitalization | $604.53M+15.7% | $547.19M+35.0% | $504.43M+13.3% | $533.84M+83.6% | $500.32M+144% | |
| Price / earnings | 10.4×-4.4× | 4.4×— | 6.1×— | 15.1×— | 189.2×— | |
| Price / sales | 4.4×-1.7× | 4.5×-5.5× | 4.7×-14.1× | 6.3×-5.5× | 8.1×-0.6× | |
| Price / book | 2.8×-1.1× | 2.7×-7.2× | 3.3×-8.0× | 4×-0.2× | 4.3×-2.0× | |
| EV / EBITDA | 5.2×— | 171.7×— | —— | —— | —— |
FAQ
- What are Zevra Therapeutics, Inc.'s profit margins?
- Zevra Therapeutics, Inc. (ZVRA) runs a 95.5% gross margin and a -103.9% operating margin, with a 42.8% net margin.
- Where do Zevra Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Zevra Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
